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HOW BIOLOGICAL AND NON-BIOLOGICAL DISEASE
MODIFYING DRUGS ARE USED IN THE TREATMENT OF
RHEUMATOID ARTHRITIS
INTRODUCTION

Esther Mantel

Rheumatoid arthritis is a long-term disease that leads to chronic inflammation
of the joints and the surrounding tissue. Effects of the inflammation are pain and
destruction of the bone and cartilage, which leads to severe disability and, possibly,
shorter life expectancy. That is why early diagnosis and aggressive treatment is a
fundamental strategy to stop the progression of the disease and suppress the
inflammation before the damage is irreversible.
In an attempt to avoid invasive treatments like arthroscopies and surgeries, the
orthopedist’s first choice of non-pharmacological treatments includes physical and
occupation therapies. Pharmaceutical treatments such as non-steroidal antiinflammatory drugs (NSAIDs) and non-opioid analgesics (pain medication such as
acetaminophen and aspirin) work on reducing the inflammation caused by rheumatoid
arthritis, which often results in pain relief. Glucocorticoids, a class of steroid
hormones, also possess anti-inflammatory effects and were once considered the most
powerful treatment of inflammatory arthritis, but their use was virtually abandoned
due to their association with toxicity; they are only used nowadays in controlling acute
flare-ups joint disease. While these therapeutic strategies reduce inflammation and
pain caused by rheumatoid arthritis, they are not that beneficial in slowing down the
joint and bone damage and the progression of the disease. Rheumatologists didn’t
realize that while the pain was being covered by the medications and antiinflammatory drugs, the inflammation and pannus (an abnormal layer of tissue) were
continuing to cultivate inside the patients joints and articular tissue. For this reason, a
new and very important group of agents called disease modifying anti-rheumatic
drugs, or DMARDs, have become a major interest as a potential new therapy in the
treatment of rheumatoid arthritis.
While most treatments focus on reducing the inflammation already present in
the bone tissue and joints, DMARDs work on slowing down occurring bone damage
and the progression of the disease by actually modifying the disease itself (Katzung
2001). They are different than other rheumatoid arthritis treatments because they
work by suppressing the underlying factors that result in synovitis, tissue reactivity,
erosions, ligament and tendon laxity, subluxations and other complications caused by
rheumatoid arthritis (Johnson 2011). Since there is no presently known cure for
rheumatoid arthritis, a lot of research is being done in finding a treatment that will stop
or at least slow the progression of the bone damage caused by the disease, so that the
patient can be in remission for a long period of time.

DISCUSSION

Rheumatoid arthritis is an autoimmune disease that affects the synovia of joints
and, eventually, the healthy surrounding tissue and bone, resulting in symmetric and
erosive polyarthritis. According to Shah and Clair (2011), rheumatoid arthritis affects
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approximately 0.5-1% of the adult population worldwide. The ratio of rheumatoidarthritis-affected women to rheumatoid-arthritis-affected men at premenopausal age is
4:1 while the same ratio at postmenopausal age is 1:1; this is attributed to the role that
estrogen has in stimulating tumor necrosis factor-#, a major cytokine in the rheumatoid
arthritis pathogenesis (Shah and Clair 2011). The exact etiology of rheumatoid
arthritis is still unknown. It is known, however, that genetics plays some role in
development and severity in certain patients. It remains a matter of debate whether the
trigger of the disease is an exogenous infectious agent, a break in immune tolerance
leading to classical autoimmunity, or simply random proceedings that accumulate with
age (Klippel 2001).
While the auto-antigen that triggers rheumatoid arthritis has not been identified
yet, the progression and evolution of the disease can be blamed on immune cells and
mediators that contribute to the inflammation response that occurs. The process of
how inflammation and erosion develop in synovial tissue and periarticular bone has
been studied and researched in patients with rheumatoid arthritis. The primary agents
involved in the immune response in rheumatoid arthritis patients are T-cells, which
mainly function in stimulating other cells in the joint to produce and secrete cytokines.
The most important cytokines involved in rheumatoid arthritis are tumor necrosis
factor (TNF) and interleukin-1 (IL-1), both produced by macrophages and synovial
lining cells that were activated by the T-cells in the joints. Once released, TNF and IL1 stimulate the synovial cells to proliferate and produce factors contributing to the
destruction of cartilage, such as inflammatory mediators and matrix
metalloproteinases, which are endopeptidases. Eventually, bone destruction is caused
by osteoclasts activated by a TNF ligand called RANKL (Receptor activator of
nuclear factor kappa-B ligand), which is produced by T-cells and synovial fibroblasts.
As the hyperplastic and hypertrophy synovium grows over the articular surface,
pannus develops, which stimulates the resorption of surrounding cartilage (Kumar et
al. 2005).
In addition to T-cells acting up, activated B-cells produce inflammatorycontributing autoantibodies. Some rheumatoid arthritis patients possessor develop
rheumatoid factors, auto-antibodies that bind to the Fc fragment of Immunoglobulin G
to form immune complexes that lead to the recruitment of polymorphonuclear
leukocytes, further exacerbating the ongoing inflammation. The increasing pannus and
inflamed synovium that spread over the articular cartilage produce large amounts of
degradative enzymes (e.g. collagenase and stromelysin) that assist in irreversible
cartilage destruction and subchondral bone erosion (Heaverstock and Jorizzo 2008).
Since it is a systemic disease, rheumatoid arthritis can affect internal organs as
well, eventually leading to early death if left untreated. Rheumatoid arthritis typically
affects joints of the hands and feet first, but can spring up in larger joints at any time.
One of the essential factors of diagnosing rheumatoid arthritis is stiffness and soreness
in the mornings after an extended lack of movement. Other clinical findings of
rheumatoid arthritis are morning pain and swelling in areas such as the phalanges and
on the balls of the feet. Routine morning activities, such as brushing ones teeth or hair,
might become difficult due to the clinical manifestations. If left untreated, the disease
will progress and result in increasing pain, swelling and stiffness caused by the
destruction of the joints and healthy bones. Figure 1 shows irreversible bone and
cartilage loss due to untreated rheumatoid arthritis.
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DISEASE MODIFYING ANTI-RHEUMATOID DRUGS (DMARDS)
DMARDs are a class of drugs that
include a diverse group of non-biological and
biological agents. Although both work on
suppressing the underlying cause of the
inflammation in the disease, biological
DMARDs are protein therapeutics that are
designed mainly to target cytokines and cellsurface
molecules
that
promote
the
inflammation response (Shah and Clair 2011).
It may take 6 weeks to 6 months for the effects
of the disease-modifying therapies to become
evident since they are slow acting. It is
necessary to start the use of DMARDs very
early in the progression of the disease, since
they work by slowing the progression and not
reversing the damage already done. A large
number of rheumatoid arthritis patients can
reach remission or at least a low disease
activity with the use of a single non-biological
DMARD. However, for those patients with
moderate or high disease activity or for those
Figure 1:
who failed to respond to a single agent due to
Interphalangeal joint abnormalities.
prolonged disease duration, combinations of
Osseous erosions are evident at the radial
non-biological DMARDs are used.
and ulnar aspects of the PIP joint of the
Clinicians realized inadequate response
second finger (arrows). Soft-tissue
was
being
achieved by patients being treated
swelling and loss of interosseous space are
additional findings. Marginal erosion is
with monotherapy DMARDs, and a more
also seen on the middle phalanx at the
aggressive treatment with DMARDs was
distal interphalangeal joint (open arrow) .
essential for improving rheumatoid arthritis
Source: Kountz and Von Feldt 2007
symptoms and slowing the progression of the
disease. The use of biological DMARDs is
reserved for those who indicate poor prognosis of the disease and do not respond to
non-biological DMARDs treatment. Many patients who don’t achieve sufficient
results from either non-biological or biological DMARDS have treatment plans that
include combining a synthetic DMARD with a biological DMARD in order to reach
optimal responses from both agent types. DMARD agents are also commonly used in
combination with non-steroidal anti-inflammatory drugs to reduce present
inflammation and relieve pain.
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Rheumatologists are trying to achieve
early and sustained suppression of the disease
activity with DMARDs. They believe that
early detection of the disease and treatment
with DMARDs might negate the need for
NSAIDs and corticosteroids. Each rheumatoid
arthritis patient’s treatment is personalized,
taking into account the severity of the disease
and the potential adverse effects of the drugs.
Since toxicity is a major concern with
DMARDs, the effects of the drugs must be
closely monitored, which can cost as much as
the drug itself (Johnson 2011). Therefore, a
large amount of effort and research is being
put in to find the right combination of
DMARDs that will work best on slowing the
onset of the disease with reduction of the
inconvenience of high costs and close
monitoring. The latest research being done on
the productivity and effectiveness of single, Figure 2: The three major rheumatoid
dual, and triple combination of synthetic arthritis therapies.
DMARDs and biological DMARDs will be Source:
discussed in this paper, along with the safety http://stg.jfponline.com/ccp_article.asp?a=1&r
ef=5610ACCP_Supplement5#5610ACCP_Su
monitoring that is necessary with the use of pplement5-fig7
these drugs.
It is important to understanding the mechanism of action of each individual
drug, because DMARDs work by modifying the disease through inhibiting specific
parts and pathways of the inflammatory response that occurs in rheumatoid arthritis.
Knowing the mechanism also helps researchers decide which combination of drugs
might work well together and which ones to experiment with, resulting in the finding
of the most productive and effective treatment for the broadest variety of people.

COMMONLY USED SYNTHETIC DMARDS
Methotrexate, an analog of folic acid and of aminopterin, is the most commonly
prescribed DMARD against rheumatoid arthritis in the United States and is usually
the initial choice when using disease-modifying drugs in rheumatoid arthritis
treatment. While its mechanism of action when used at a low dose in rheumatic
diseases is unclear, it may relate to the polyglutamates metabolized from the
methotrexate that cause extracellular adenosine to be released, which has antiinflammatory and immunotherapy properties (Imboden et al. 2007). According to two
meta-analyses, methotrexate has the best efficacy/toxicity ratio.
The most important action shown in studies of methotrexate against
rheumatoid arthritis is its effects in increasing adenosine (anti-inflammatory agent)
levels, lowering the pro-inflammatory cytokine levels, and increasing the antiinflammatory cytokine levels (Swierkot and Szechinski 2006). Intensive treatment and
observation while taking methotrexate is recommended in order to attain the most
benefit from the drug. While patients tend to remain on methotrexate longer than any
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other DMARD because of better clinical responses and less toxicity, a significant
number of patients do not achieve premium control over the disease when taking the
drug alone. As a result, methotrexate can either be used as a monotherapy or in
combination with other synthetic DMARDs or anti-tumor necrosis factor agents, a
class of biological DMARDs (Imboden et al.2007).
A study was done in Japan to evaluate the effectiveness of the government
recommended 8mg/week dose of methotrexate given to people with rheumatoid
arthritis. One hundred seventy-six patients with active rheumatoid arthritis at Konan
Kakagowa Hospital and Kobe University Hospital participated in the study. The
effects of methotrexate were evaluated by the American College of Rheumatology
(ACR) core set, which showed maintained improvements in the clinical signs and
symptoms of rheumatoid arthritis for 24 months. However, according to European
League Against Rheumatism (EULAR) response criteria, 63.5% of the patients were
found nonresponsive at 24 months from the methotrexate therapy. Despite the
treatment, x-rays showed the progression of joint destruction. This study is important
because it verifies as mentioned before that many patients do not achieve sufficient
disease control when using methotrexate as a monotherapy (Hashiramoto et al. 2009).
Most combination therapies involve using another DMARD with methotrexate, to
enhance the methotrexate clinical response.
Leflunomide is another very important synthetic DMARD that is widely used.
Once administered, leflunomide is well absorbed and quickly metabolized in vivo into
A771726, which is the active form of the drug. At its molecular level, leflunomide is a
pyrimidine synthesis inhibitor that inhibits dihydroorotatedehydrogenase, an enzyme
involved in the synthesis of pyrimidines. Unlike other cells during proliferation,
lymphocytes increase their pool of pyrimidines much more than their increase in
purines, therefore synthesizing them from both salvage and de novo pathways. By
inhibiting dihydoorotatedehydrogenase, A771726 prevents the damaging lymphocytes
from accumulating enough pyrimidines to support DNA synthesis, which is why
leflunomide is considered an immunosuppressive agent.
In addition to being a pyrimidine synthesis inhibitor, current research is being
done to investigate A771726’s effect on inhibiting the over-expression ofCD147,
thereby resulting in the down-regulation of matrix metalloproteinase-2 (MMP-2) and
matrix metalloproteinase-9 (MMP-9) in active macrophages. CD147 is a member of
the immunoglobulin superfamily, which consists of autoantibodies that are linked to
autoimmune diseases such as rheumatoid arthritis. Pro-inflammatory cytokines, such
as TNF, interleukin 1 and interleukin 17 are released in patients with rheumatoid
arthritis and work synergistically to release matrix metalloproteinase-3’s (MMP3)
from fibroblast-like synoviocytes and macrophages. MMP3’s are connected to
pathologic tissue destruction, making them a vital interest to the research being done
to find a cure for rheumatoid arthritis.
Since CD147 is known to induce several MMP3’s and its expression levels
have been found elevated in the synovial membranes of rheumatoid arthritis patients,
research is being done that focuses on CD147 as a novel target in the treatment of
rheumatoid arthritis. A study was done on phorbol myristate acetate differentiated
THP-1 cells line, a monocyte-macrophage, to observe the effects of leflunomide’s
active metabolite on CD147 levels. As MMP3’s are the major MMPs secreted by
activated inflammatory macrophages and markers of progression of joint damage in
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early rheumatoid arthritis, the effects of A771726 on MMP3 gelatinases were also
evaluated in this study.
In the macrophage cell model used in the study, an increased mRNA
expression of MMP-2 and MMP-9 (both of which can be activated by MMP3)
occurred in addition to the up-regulation of CD147, once the cells differentiated. The
results found in the study showed that A771726 did not affect the mRNA expression
of CD147, but did inhibit CD147 protein expression on the cell surface in a dosage
dependent manner, which demonstrates that A771726 only has post-transcriptional
effect on CD147 production in THP-1 cells. The authors go on to suggest that future
studies should be conducted on the effect of A771726 on the glycosylation of CD147,
since abnormal glycosylation was the cause of the instability of the CD147 proteins in
their experiment. The study also showed that A771726 inhibited the induced increase
of gelatinolytic activity of MMP-2 and MMP-9. The authors conclude by saying that
their study indicates that A771726 inhibits the production of CD147 and the
gelatinolytic activity of MMP-2 and MMP-9 in THP-1 cells, and they suggest that
serum concentration of the metabolite should be monitored in rheumatoid arthritis
patients so that sufficient concentration is maintained to allow the patient to achieve
remission (Juang et al. 2011).
Leflunomide can also be given as a combo-therapy. The thought of combining
leflunomide with methotrexate as a double combination therapy was inspired by the
idea that combining methotrexate with an agent whose mechanism of action was
different than its own might produce better results than methotrexate monotherapy. In
1999, a study was done on the safety and efficacy of treating active rheumatoid
arthritis with a combination treatment of methotrexate and leflunomide. It was a 52week open-label study in which 30 patients who had active rheumatoid arthritis
despite previous methotrexate treatment participated. Adverse effects and clinical
response, as judged by the American College of Rheumatology 20% response criteria,
were assessed as end point results. Of the patients, 53% met the ACR 20% response
criteria and 2 patients met the ACR remission criteria after 1 year. While the study
was only done on 30 patients and only a little more than half the patients met the ACR
criteria, the study did introduce methotrexate and leflunomide combination therapy as
a potential rheumatoid arthritis treatment (Mroczkowski et al. 1999).
In 2004, another study was done on the safety and efficacy of the combination
therapy of leflunomide with methotrexate. After a 24-week, randomized, double blind
trial of taking leflunomide or a placebo with methotrexate, the patients could enter a
24-week extension to continue the study. Results showed a 48-week maintained
response to therapy for those patients who continued to receive leflunomide plus
methotrexate. ACR 20% responder rates improved in the patients who switched from
taking placebos to leflunomide. Similar ACR 20% response rates were found between
patients who switched from placebo to leflunomide without a loading dose to those
who received a randomized loading dose of leflunomide. However, fewer adverse
events of diarrhea and nausea were found in those who did not receive the extra dose.
In addition, patients who switched from placebo to leflunomide in the extension
exhibited a lower incidence of elevated transaminases compared to the patients who
were initially taking leflunomide throughout the 48-week trial, which may indicate
possible hepatotoxicity caused by leflunomide (Kremer et al. 2004). While leflunomide
might slow the progression of the disease, patients must discuss with their doctors
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required monitoring and possible combination therapies that will yield the best
efficacy/toxicity ratio while taking leflunomide.
Besides for leflunomide and methotrexate, there are other synthetic DMARDs
used to treat rheumatoid arthritis. Both sulfasalazine and hydroxychloroquine were
initially developed for other disease like inflammatory bowel disease and malaria, but
they were coincidentally found to be effective in rheumatoid arthritis. They are weak
DMARDs, which is why they are usually only used as monotherapy in the early stages
of rheumatoid arthritis or used in combination with other DMARDs such as
methotrexate. With the use of hydroxychloroquine, ophthalmologic examinations are
required every six to twelve months to detect color change or evidence of drug in the
retina. Sulfasalazine, the most common used DMARD in Europe, is usually combined
with methotrexate, hydroxychloroquine, or both. It is recommended that blood cell
counts, especially white blood cell counts, be monitored in the first six months of
taking sulfasalazine.
Required monitoring while taking these drugs is evidence of how expensive and
time-consuming DMARD treatments can be. This is why such an abundant amount of
research is being done to find the most effective and convenient DMARD treatment
against the autoimmune disease.
A study was done to compare the efficacy of double or triple combination
therapies involving methotrexate, sulfasalazine and hydroxychloroquine in patients
with rheumatoid arthritis. Combinations of the different therapies were either
methotrexate (MTX) with hydroxychloroquine (HCQ), MTX with sulfasalazine
(SSZ), or the triple combination of MTX, HCQ and SSZ. One hundred seventy-one
rheumatoid arthritis patients who were not previously treated with the medications
were randomized to receive one of the three treatment combinations in this 2-year,
double blind, and placebo controlled trial. The end point goal was to find the
percentage of patients after 2 years who had a 20% response to their assigned therapy
according to the American College of Rheumatology. While all combination treatments
were well-tolerated, patients receiving the triple treatment responded best with 78% of
them achieving the 20% ACR response required, compared to the 60% percent of
those receiving MTX and HCQ and only 49% of those receiving MTX and SSZ
(O’Dell et al. 2002).

COMMONLY USED BIOLOGICAL DMARDS

Pro-inflammatory cytokines, especially tumor necrosis factor-# and interleukin1, have vital roles in the pathophysiology of rheumatoid arthritis. This fact led to the
development of biological agents that target TNF-# and interleukin-1 cytokines. In
addition, recent research has been done that shows promise for therapies that block Tcell co-stimulation and those that target B-cells. Since biological disease modifying
anti-rheumatoid drugs have only recently been studied, and possible long-term adverse
effects are still unknown, they are usually saved for use in combination therapies with
other DMARDs such as methotrexate and leflunomide, for those rheumatoid arthritis
patients who did not respond to synthetic DMARD monotherapy.
DMARDs that are anti TNF-# agents include etanercept, infliximab, and
adalimumab. Etanercept, a protein genetically engineered from a fusion gene, consists
of two soluble TNF p75 receptor functional groups linked to the Fc portion of human
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immunoglobulin-1. It binds to TNF-# molecules, thereby preventing the activation of
the inflammatory cascade, in addition to inhibiting lymphotoxin-# (O’Dell 2007).
A study was done on the efficacy of etanercept combination therapy with
methotrexate, where 89 patients previously treated with methotrexate, who still
showed signs of active rheumatoid arthritis symptoms, were randomly assigned to
receive either etanercept or placebo subcutaneously, while continuing methotrexate
therapy. At 24 weeks ACR response criteria was used to measure clinical response in
improvements. Results showed that at 24 weeks 71% of the patients receiving
etanercept-MTX combination therapy met the ACR 20% response criteria, compared
to 27% of the group receiving placebo plus MTX. Thirty-nine percent of the
etanercept group reached ACR 50% response criteria compared to the 3% of the
placebo group. Significantly better outcomes, according to all measures of disease
activity, were present in the patients receiving the etanercept-MTX combination
therapy. Adverse effects associated with etanercept in this trial included only mild
injection-site reactions, showing etanercept as a safe and potential combination therapy
in patients with active rheumatoid arthritis who didn’t respond sufficiently enough to
methotrexate therapy alone (Weinblatt et al. 1999).
Infliximab is a 25% mouse and 75% human monoclonal antibody that bind to
soluble and membrane bound TNF-# cytokines with high affinity, preventing them
from interacting with their receptors, resulting in the down-regulation of macrophage
and T cell function.
Adalimumab is a recombinant human anti-TNF antibody. By combining with
TNF-#, it prevents its interaction with its p77 and p75 cell surface receptors, resulting
in the down-regulation of macrophage and T-cell function, which is similar to
infliximab’s mechanism of action (Furst et al. 2009). A 24-week, randomized, doubleblind, placebo-controlled study was done in 2002 to test the efficacy and safety of
adalimumab in combination with MTX given to patients with active rheumatoid
arthritis who have not responded adequately to previous MTX mono treatment. The
results showed that an ACR 20%, 50% and 70% response were all achieved by a
significantly greater proportion of patients in the adalimumab plus MTX administered
group than in the groups given placebos with MTX. The greater the dose of
adalimumab was given, increasing from 20-mg to 40-mg, to 80-mg, respectively, the
higher the response rate appeared. Response seemed rapid, as the greatest proportion
of adalimumab-treated patients achieving an ACR 20% response occurred at the first
scheduled visit of one week. Adverse events were similar in both control groups,
indicating that adalimumab was well tolerated (Weinblatt et al. 2003).
While this clinical trial did demonstrate that adalimumab with combined MTX
therapy has been effective in reducing signs and symptoms of active rheumatoid
arthritis, and does give hope for potential combination therapy, the study was only
held for 24 weeks. While this might be sufficient to show improvements caused by
adalimumab in rheumatoid arthritis symptoms, it does not show how effective
adalimumab is in the long run at stopping the progression of the disease, or pushing
the patient into remission (Kremer et al. 2008).
Abatacept, a recombinant protein, acts by blocking T-cell co-stimulation and
preventing the autoimmune response caused by rheumatoid arthritis. A study was
done on 652 patients who had active rheumatoid arthritis, despite previously being
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treated with methotrexate, to see the efficacy of abatacept. 433 patients were randomly
assigned to be given an infusion of a fixed dose of abatacept once a month, while 219
received placebos. Results showed at one year, progression of structural joint damage
was statistically slowed by abatacept. Physical function significantly improved in
63.7% of the patients. While these results seem to be very promising for abatacept
therapy, the study only involved 1 group of patients over 1 year and therefore is very
limited in its evidence of the efficacy of the drug. Longer treatment in different
populations is needed to establish its effectiveness against the progression of
rheumatoid arthritis (Kremer et al. 2008).
Rituximab is a genetically engineered humanized mouse monoclonal antibody
that works against CD20 molecules on the B-cell surfaces, thereby depleting the Bcells, stopping their immune response and thereby reducing inflammation (Furst et al.
2009). The advantage of rituximab is that it works on B-cells rather than inhibiting
TNF cytokines, which is a relief to patients who do not benefit from anti-TNF agents,
either at the start of treatment or after receiving some treatment. A study was done in
Finland to examine the effectiveness of rituximab on rheumatoid arthritis patients who
failed to respond to TNF antagonists, or had a contraindication to these drugs. Data
was collected from five rheumatology clinics and examined 81 patients in total who
were treated with rituximab from April 2005 to June 2008, since previous therapies
were unsuccessful in reaching adequate responses. Treatment response was defined
according to EULAR response criteria and disease activity score using 28 joint counts
(DAS28). The results of the trial showed adequate EULAR response in 77% of the
patients and a suppressed DAS28 score of 2.08 units. Since the percentage of good
responses of patients taking DMARDs other than methotrexate with rituximab, was
somewhat higher than those taking methotrexate alone with rituximab, it’s obvious
that rituximab is equally effective when combined with methotrexate and other
DMARDs. The study concludes that rituximab was effective in controlling disease
activity in patients who did not show adequate results taking other DMARDs alone
(Valleala et al. 2009).
Tocilizumab is the first of its kind as an anti-interleukin 6 receptor monoclonal
antibody. Interleukin 6, a pro-inflammatory cytokine that is released by immune,
endothelial and synovial cells, induces osteoclast differentiation, therefore contributing
to the joint and bone destruction occurring in rheumatoid arthritis patients. The drug
is typically given with or without methotrexate, for patients who did not respond to
single or multiple anti-TNF therapies. Similarly to those associated with other
monoclonal immune suppressors, adverse effects include infusion reactions,
development of neutralizing antibodies, hypersensitivity reactions, and increased risk
of serious infection (Murri 2010).
Studies done on rheumatoid arthritis patients who took tocilizumab with
methotrexate revealed positive results. One study was done on 499 patients who had
an inadequate response to one or more anti-TNF agents. Results after the 24 weeks
showed that 50.0% of those who received 8mg of tocilizumab achieved ACR 20%
response criteria, compared to the 30.4% in the 4mg group and the 10.1% in the
placebo group. At week four, ACR 20% response criteria was reached by more
patients receiving 8mg of tocilizumab than those in the control groups, as was DAS28
remission rates achieved at week 24. The most common adverse events reported in the
trial were infections, gastrointestinal symptoms, rash and headaches; however, most

How Biological and Non-biological Disease Modifying Drugs

117

were mild and moderate. This study demonstrates the potential benefit of tocilizumab
given with methotrexate as an effective therapy against rheumatoid arthritis (Emery
et al 2008). Results showed rapid and sustained improvements of rheumatoid arthritis
symptoms for those who failed to respond well to TNF antagonists and reported mild
adverse effects.
Even though the biological DMARDs mentioned above did show promising
trial results when given with methotrexate, biological DMARDs are so fresh and new
in research that efficacy and adverse effects are unable to be studied in the long run.
Most of these trials are over a 1 to 2 year period, which is not an adequate amount of
time to measure achievable long-term remission induced by these therapies. While they
definitely show great potential in slowing down the progression of bone destruction
and active symptoms caused by rheumatoid arthritis, more research and long-term
studies must be done to evaluate the lasting effects and possible negative side effects of
these young progressing therapies.

ADVERSE EFFECTS AND DISADVANTAGES

Potential increased risk of serious infection is one of the major side effects of
biological DMARDs. TNF inhibitors in particular have been noticed to increase the
risk of developing reactivation of dormant tuberculosis. This is why it is important for
a patient who is about to start on anti-TNF agents to undergo tuberculin skin testing
and even chest radiographs, if needed. A national prospective observational study was
done on data collected from the British Society for Rheumatology Biologics Register
(BSRBR) to test if different anti-TNF agents increase the risk of tuberculosis
reactivity. A comparison of TB rates in 10712 patients who were either treated with
etanercept, infliximab, or adalimumab showed three-to four-fold higher TB rates in
patients taking infliximab and adalimumab, than those receiving etanercept (Dixon et
al. 2010).
Another prospective observational study was done from the BSRBR, where
11,881 patients treated with anti-TNF agents were evaluated to research an increased
risk of septic arthritis. While the results did not show that anti-TNF therapy was a
significant cause of Septic Arthritis, they did find that it was associated with doubling
the risk of developing SA.
Both studies were done on an enormous number of subjects who might have
had different contributing factors in developing tuberculosis or septic arthritis
(Galloway et al. 2011). While these studies do not positively prove that anti-TNF
agents used in rheumatoid arthritis patients increase the risk of infection and
tuberculosis, they do show a probable basis for the fact that TNF inhibitors might
contribute to these risks. For this reason, physicians and surgeons should be aware of
these potentially life-threatening complications, and instruct their patients on how to
manage and prevent these adverse outcomes.
The cost of DMARDs and the necessary monitoring required while being
treated with these drugs can be extremely expensive and burdensome, especially for
elderly patients with severe rheumatoid arthritis. A large amount of monitoring is
needed while on DMARD treatment, since complications such as infection and
toxicity can occur. Tests such as CBCs and platelet counts are necessary periodically
to rule out infection, and yearly ophthalmologic tests are needed for patients on
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hydroxychloroquine. All in all, sometimes the excessive expense and adverse effects
might prevent patients from benefiting from these new and promising treatments.

CONCLUSION
Rheumatoid arthritis can be a crippling and incapacitating disease, if left
untreated. Disease modifying anti-rheumatic drugs work in the unconventional way of
modifying the disease and inhibiting the underlying cause of inflammation present in
rheumatoid arthritis, in order to reach sustainable remission. While it is a relatively
new group of drugs, an abundant amount of research and effort has been put in to find
the most suitable and effective treatment when using these agents. From the studies
mentioned above, it is obvious that DMARDs has a tremendous potential of becoming
the leading treatment in autoimmune inflammatory disease, such as rheumatoid
arthritis. According to Tak et al. (2011), the complex and varied mechanism of actions
of these drugs make it necessary for researchers to study the different mechanism and
contemplate which combinations are effective and safe. What’s more, rheumatologists
should put effort in predicting clinical responses of individual patients who they
prescribe DMARDs to. By doing so, the physician may very possibly maximize the
patient’s outcome, minimize safety concerns and reduce treatment costs caused by
complications (Tak et al. 2011). Even though there is a long way to go, DMARDs are
thriving at helping people overcome rheumatoid arthritis, and show great potential in
some day reaching the ultimate goal of causing rheumatoid arthritis patients to go into
permanent remission, thus becoming the cure for rheumatoid arthritis.
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